Page 113 - Medicare Benefit Policy Manual
P. 113

410.31.  Denials as not reasonable and necessary can be found at §1862(a)(1)(A) of the
                   Act, 42 CFR 410.31(e), and 42 CFR 411.15(k).

                   80.5.3 - Definition
                   (Rev. 70, Issued: 05-11-07, Effective: 01-01-07, Implementation: 07-02-07)

                   BMM means a radiologic, radioisotopic, or other procedure that meets all of the
                   following conditions:

                          •  Is performed to identify bone mass, detect bone loss, or determine bone
                              quality.

                          •  Is performed with either a bone densitometer (other than single-photon or
                              dual-photon absorptiometry) or a bone sonometer system that has been cleared
                              for marketing for BMM by the Food and Drug Administration (FDA) under
                              21 CFR part 807, or approved for marketing under 21 CFR part 814.

                          •  Includes a physician’s interpretation of the results.

                   80.5.4 - Conditions for Coverage
                   (Rev. 70, Issued: 05-11-07, Effective: 01-01-07, Implementation: 07-02-07)

                   Medicare covers BMM under the following conditions:

                   1.  Is ordered by the physician or qualified nonphysician practitioner who is treating the
                       beneficiary following an evaluation of the need for a BMM and determination of the
                       appropriate BMM to be used.

                       A physician or qualified nonphysician practitioner treating the beneficiary for
                       purposes of this provision is one who furnishes a consultation or treats a beneficiary
                       for a specific medical problem, and who uses the results in the management of the
                       patient.  For the purposes of the BMM benefit, qualified nonphysician practitioners
                       include physician assistants, nurse practitioners, clinical nurse specialists, and
                       certified nurse midwives.

                   2.  Is performed under the appropriate level of physician supervision as defined in 42
                       CFR 410.32(b).

                   3.  Is reasonable and necessary for diagnosing and treating the condition of a beneficiary
                       who meets the conditions described in §80.5.6.

                   4.  In the case of an individual being monitored to assess the response to or efficacy of an
                       FDA-approved osteoporosis drug therapy, is performed with a dual-energy x-ray
                       absorptiometry system (axial skeleton).
   108   109   110   111   112   113   114   115   116   117   118